STTCOMP DXB FA LONG Medical /Bio stock ann today with Japanese entity Fuso for a development and licensing agreement to commercialize DMX-200. Development drug for kidney disease. DMX to receive 107 million AU in upfront payments for development and sales milestones plus royalties. Staggered as milestones reached. 3RD such agreement signed and looks good going forward to land the U.S and China in future deals. So far the agreements and milestones on the 3 deals has the future potential to bring in 458 million in milestone fees plus royalties. Med stocks can be not for the faint of heart and can take forever to reach goals but this mob kicking plenty of them
